Anupam Rama
Stock Analyst at JP Morgan
(3.37)
# 959
Out of 4,960 analysts
270
Total ratings
44.04%
Success rate
4.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $13 | $5.93 | +119.22% | 8 | Aug 14, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $20 → $17 | $9.74 | +74.54% | 5 | Aug 14, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $28 → $29 | $5.76 | +403.47% | 5 | Aug 14, 2025 | |
| KOD Kodiak Sciences | Upgrades: Neutral | $15 | $10.20 | +47.06% | 7 | Aug 14, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $56 → $53 | $22.57 | +134.82% | 10 | Aug 7, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $29 → $30 | $12.12 | +147.52% | 7 | Aug 7, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $35 → $37 | $27.97 | +32.28% | 17 | Aug 4, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $140 → $145 | $135.43 | +7.07% | 18 | Jul 31, 2025 | |
| RAPT RAPT Therapeutics | Upgrades: Neutral | $14 | $11.32 | +23.73% | 8 | Jul 30, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Neutral | $24 | $20.22 | +18.69% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $72 | $25.12 | +186.62% | 9 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $20.22 | +295.65% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 → $9 | $5.67 | +58.73% | 10 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $29.78 | +292.88% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $50 | $49.08 | +1.87% | 9 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $41 | $16.24 | +152.46% | 10 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $51 | $35.04 | +45.55% | 12 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $34 | $7.20 | +372.22% | 4 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $17.92 | +145.54% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $13.49 | +122.39% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $17 | $7.61 | +123.39% | 13 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $33.75 | +18.52% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $125 | $76.08 | +64.30% | 6 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.41 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.63 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $2.12 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $2.31 | +462.77% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $90 | $6.45 | +1,295.35% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $12.20 | +1,949.18% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.54 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $38.34 | +51.28% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $13.91 | -13.73% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $4.58 | +707.86% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $57.48 | -4.31% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.60 | +1,650.00% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $38.80 | +39.18% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.36 | +12,533.35% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $12.58 | +114.63% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $10.19 | +292.54% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $454.38 | -69.85% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $39 | $8.53 | +357.21% | 1 | Dec 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $9.07 | +429.22% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.50 | - | 2 | May 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $18 | $0.41 | +4,320.43% | 2 | Mar 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.91 | +3,184.07% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $50.57 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.27 | - | 2 | Jul 21, 2017 |
Solid Biosciences
Aug 14, 2025
Maintains: Overweight
Price Target: $15 → $13
Current: $5.93
Upside: +119.22%
ORIC Pharmaceuticals
Aug 14, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $9.74
Upside: +74.54%
Olema Pharmaceuticals
Aug 14, 2025
Maintains: Overweight
Price Target: $28 → $29
Current: $5.76
Upside: +403.47%
Kodiak Sciences
Aug 14, 2025
Upgrades: Neutral
Price Target: $15
Current: $10.20
Upside: +47.06%
Vera Therapeutics
Aug 7, 2025
Maintains: Overweight
Price Target: $56 → $53
Current: $22.57
Upside: +134.82%
Cogent Biosciences
Aug 7, 2025
Maintains: Overweight
Price Target: $29 → $30
Current: $12.12
Upside: +147.52%
Apellis Pharmaceuticals
Aug 4, 2025
Maintains: Overweight
Price Target: $35 → $37
Current: $27.97
Upside: +32.28%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Neutral
Price Target: $140 → $145
Current: $135.43
Upside: +7.07%
RAPT Therapeutics
Jul 30, 2025
Upgrades: Neutral
Price Target: $14
Current: $11.32
Upside: +23.73%
Sarepta Therapeutics
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $20.22
Upside: +18.69%
Jul 28, 2025
Maintains: Overweight
Price Target: $66 → $72
Current: $25.12
Upside: +186.62%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $20.22
Upside: +295.65%
Jul 22, 2025
Downgrades: Neutral
Price Target: $19 → $9
Current: $5.67
Upside: +58.73%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $29.78
Upside: +292.88%
Mar 24, 2025
Maintains: Overweight
Price Target: $44 → $50
Current: $49.08
Upside: +1.87%
Mar 20, 2025
Maintains: Overweight
Price Target: $39 → $41
Current: $16.24
Upside: +152.46%
Mar 13, 2025
Maintains: Overweight
Price Target: $44 → $51
Current: $35.04
Upside: +45.55%
Mar 5, 2025
Maintains: Overweight
Price Target: $39 → $34
Current: $7.20
Upside: +372.22%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $17.92
Upside: +145.54%
Feb 25, 2025
Initiates: Overweight
Price Target: $30
Current: $13.49
Upside: +122.39%
Nov 12, 2024
Maintains: Overweight
Price Target: $16 → $17
Current: $7.61
Upside: +123.39%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $33.75
Upside: +18.52%
Oct 4, 2024
Maintains: Overweight
Price Target: $100 → $125
Current: $76.08
Upside: +64.30%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.41
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.63
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $2.12
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $2.31
Upside: +462.77%
Aug 16, 2023
Maintains: Neutral
Price Target: $80 → $90
Current: $6.45
Upside: +1,295.35%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $12.20
Upside: +1,949.18%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $7.54
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $38.34
Upside: +51.28%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $13.91
Upside: -13.73%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $4.58
Upside: +707.86%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $57.48
Upside: -4.31%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $1.60
Upside: +1,650.00%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $38.80
Upside: +39.18%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.36
Upside: +12,533.35%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $12.58
Upside: +114.63%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $10.19
Upside: +292.54%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $454.38
Upside: -69.85%
Dec 24, 2019
Initiates: Overweight
Price Target: $39
Current: $8.53
Upside: +357.21%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $9.07
Upside: +429.22%
May 10, 2018
Upgrades: Overweight
Price Target: n/a
Current: $10.50
Upside: -
Mar 6, 2018
Maintains: Overweight
Price Target: $15 → $18
Current: $0.41
Upside: +4,320.43%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $0.91
Upside: +3,184.07%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $50.57
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $1.27
Upside: -